Q2 EPS Estimate for TScan Therapeutics Lowered by Analyst

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a report released on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.32) for the quarter, down from their previous estimate of ($0.31). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.30) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.30) EPS.

Several other analysts have also commented on TCRX. Needham & Company LLC dropped their price target on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Barclays dropped their target price on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Wedbush restated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, TScan Therapeutics has a consensus rating of “Buy” and an average price target of $9.20.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX opened at $1.98 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The firm’s 50 day simple moving average is $2.41 and its 200-day simple moving average is $3.99. TScan Therapeutics has a 12 month low of $1.82 and a 12 month high of $9.69. The stock has a market capitalization of $105.67 million, a price-to-earnings ratio of -1.87 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $1.43 million.

Institutional Trading of TScan Therapeutics

Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new position in TScan Therapeutics in the 4th quarter valued at about $32,000. Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the fourth quarter valued at approximately $32,000. ProShare Advisors LLC purchased a new position in shares of TScan Therapeutics in the fourth quarter valued at approximately $40,000. Wells Fargo & Company MN boosted its stake in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after acquiring an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of TScan Therapeutics during the fourth quarter worth approximately $59,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.